Scarica l'app Stockscreener
16.25
2.14%
0.34
Pre-mercato:
16.30
0.05
+0.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Precedente Chiudi:
$15.91
Aprire:
$15.88
Volume 24 ore:
902.78K
Relative Volume:
0.36
Capitalizzazione di mercato:
$1.15B
Reddito:
-
Utile/perdita netta:
$-145.21M
Rapporto P/E:
-7.0652
EPS:
-2.3
Flusso di cassa netto:
$-140.12M
1 W Prestazione:
-0.49%
1M Prestazione:
+17.50%
6M Prestazione:
-70.49%
1 anno Prestazione:
-63.80%
Intervallo 1D:
$15.86
$16.45
Intervallo di 1 settimana:
$15.20
$16.86
Portata 52W:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Nome
Moonlake Immunotherapeutics
Settore
Industria
Telefono
41 41 510 8022
Indirizzo
DORFSTRASSE 29, ZUG
Confronta MLTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
16.25 | 1.13B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-15 | Downgrade | Goldman | Neutral → Sell |
| 2026-01-09 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-11-03 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Downgrade | Goldman | Buy → Neutral |
| 2025-09-30 | Downgrade | Citigroup | Buy → Neutral |
| 2025-09-30 | Downgrade | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2025-09-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Downgrade | Stifel | Buy → Hold |
| 2025-07-28 | Iniziato | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-11-05 | Ripresa | Wedbush | Outperform |
| 2024-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-11-02 | Iniziato | Stifel | Buy |
| 2023-09-14 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Iniziato | Needham | Buy |
| 2023-06-15 | Iniziato | Barclays | Equal Weight |
| 2023-05-01 | Iniziato | Guggenheim | Buy |
| 2023-03-22 | Iniziato | Wedbush | Outperform |
| 2023-03-09 | Iniziato | BTIG Research | Buy |
| 2023-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Iniziato | Bryan Garnier | Buy |
| 2022-11-11 | Iniziato | Jefferies | Buy |
| 2022-08-25 | Iniziato | SVB Leerink | Outperform |
| 2022-07-21 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Iniziato | Cowen | Outperform |
Mostra tutto
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
Can MoonLake Immunotherapeutics keep up with sector leadersMarket Activity Recap & AI Based Buy/Sell Signal Reports - mfd.ru
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
(MLTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Risk Analysis: What is the implied volatility of JWEL2025 Bull vs Bear & High Yield Stock Recommendations - baoquankhu1.vn
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.6%Here's What Happened - MarketBeat
Zacks Research Downgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to Strong Sell - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab - MSN
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
MoonLake shares surge after FDA outlines approval route for HS therapy - MSN
Forecast Cut: Can TRINI deliver alphaRate Cut & Risk Managed Investment Entry Signals - baoquankhu1.vn
MoonLake Immunotherapeutics (MLTX) Is Down 7.4% After FDA Clears HS BLA Path Using Existing Trials - simplywall.st
MoonLake Immunotherapeutics (MLTX) Valuation After FDA BLA Green Light And Split Analyst Reactions - simplywall.st
Moonlake surges as no additional studies are required for lead drug - MSN
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action - TMX Newsfile
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap DownHere's Why - MarketBeat
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns By Investing.com - Investing.com South Africa
MoonLake downgraded to Sell at Goldman Sachs (MLTX:NASDAQ) - Seeking Alpha
Goldman Sachs Downgrades MoonLake Immunotherapeutics(MLTX.US) to Sell Rating, Raises Target Price to $10 - 富途资讯
Goldman Sachs Downgrades MLTX, Raises Price Target to $10.00 | M - GuruFocus
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns - Investing.com Canada
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs - TipRanks
MACD Signal: Is MoonLake Immunotherapeutics stock suitable for long term investingTrade Risk Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Stop Loss: Is IGMS benefiting from interest rate changes2025 Big Picture & Detailed Earnings Play Strategies - baoquankhu1.vn
Exit Recap: Will MoonLake Immunotherapeutics stock continue upward momentumOil Prices & Safe Capital Growth Stock Tips - moha.gov.vn
Death Cross: How is MoonLake Immunotherapeutics managing supply chain issues2025 Bull vs Bear & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Buyback Watch: What is the Moat Score of MoonLake ImmunotherapeuticsMarket Sentiment Summary & Risk Controlled Stock Alerts - baoquankhu1.vn
Guidance Update: Why MoonLake Immunotherapeutics stock could rally in 2025Take Profit & AI Powered Market Trend Analysis - Bộ Nội Vụ
Published on: 2026-01-13 06:01:31 - Улправда
(MLTX) Risk Channels and Responsive Allocation - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 7.3%Time to Sell? - MarketBeat
MLTX stock extends rally as FDA feedback spurs bullish brokerage action – retail speculates on potential M&A conversations - MSN
Why MoonLake Immunotherapeutics (MLTX) Is Up 54.7% After FDA Opens Path to HS BLA Filing - simplywall.st
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $32 - 富途牛牛
BTIG Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24 - 富途资讯
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Clears Existing Data For Sonelokimab BLA In Hidradenitis Suppurativa - simplywall.st
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations - Stocktwits
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $20 to $45 - 富途牛牛
MoonLake Options Trading: A Deep Dive into Market Sentiment - Benzinga
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 9.6%Time to Buy? - MarketBeat
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal - BioPharma Dive
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation - FinancialContent
Tranquility Restored For MoonLake With Positive FDA Feedback On HS Drug - Citeline News & Insights
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Buy Rating at HC Wainwright - MarketBeat
MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission (NASDAQ:MLTX) - Seeking Alpha
MLTX Analyst Rating: HC Wainwright & Co. Raises Price Target to $32.00 | MLTX Stock News - GuruFocus
BTIG Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq
Moonlake Immunotherapeutics stock upgraded to Buy at BTIG on FDA feedback - Investing.com Nigeria
Will MoonLake's Clinical Milestones Send Investors Over The Moon? - RTTNews
Will MoonLake Immunotherapeutics stock benefit from AI adoptionJuly 2025 Update & High Conviction Trade Alerts - ulpravda.ru
Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):